MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 528.9 USD | -0.27% |
|
-2.66% | +14.23% |
| Apr. 30 | Citigroup Adjusts Price Target on McKesson to $620 From $575 | MT |
| Apr. 24 | McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.23 for the 2024 fiscal year.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company benefits from high valuations in earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +14.23% | 69.5B | C+ | ||
| +7.11% | 8.2B | B | ||
| -20.55% | 7.97B | B- | ||
| -4.06% | 7.84B | C | ||
| +2.26% | 4.66B | B- | ||
| +17.12% | 4.32B | B+ | ||
| +1.41% | 4.19B | B- | ||
| -3.02% | 3.89B | B | ||
| +21.42% | 3.62B | C+ | ||
| +8.64% | 3.41B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MCK Stock
- Ratings McKesson Corporation
